(UroToday.com) Following the presentation from Dr. Sandu of the preliminary results of the PRINCE trial of 177Lu-PSMA-617 in Combination with Pembrolizumab for Metastatic Castration-Resistant Prostate Cancer (mCRPC), Dr. Mateo provided an invited discussion to contextualize these results in the Proffered Paper session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate cancer genitourinary tumors.